journal article·2025-01Open access

Differential effects of macrophage subtype‐specific cytokines on fibroblast proliferation and endothelial cell function in co‐culture system

Ilaha Isali, Phillip McClellan, Thomas R. Wong, Sara Hijaz, David R. Fletcher, Guiming Liu, Tracey L. Bonfield, James M. Anderson, Adonis Hijaz, Ozan Akkus

Abstract

Abstract Macrophages are involved in several critical activities associated with tissue repair and regeneration. Current approaches in regenerative medicine are focusing on leveraging the innate immune response to accelerate tissue regeneration and improve long‐term healing outcomes. Of particular interest in this regard are the currently known, four main M2 macrophage subtypes: M2interleukin (IL)‐4,IL‐13, M2IC, M2IL‐10, M2non‐selective adenosine receptor agonists (NECA) (M2IL‐4,IL‐13 → M2NECA). In this study, rat bone marrow‐derived macrophages (M0) were polarized to each of the four subtypes M2IL‐4,IL‐13 → M2NECA and cultured for 72 h in vitro. Luminex assay results highlighted increased production of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for M2IL‐4,IL‐13, higher amounts of transforming growth factor‐beta 1 (TGF‐β1) for M2IL‐10, and elevated vascular endothelial growth factor A (VEGF‐A) from M2NECA. Co‐culture experiments performed with M2IL‐10 macrophages and L929 fibroblasts highlighted the increased production of soluble collagen within the media as well as higher amounts of collagen in the extracellular matrix. Human umbilical vein endothelial cells (HUVECs) were co‐cultured with M2NECA macrophages, which demonstrated an increase in intercellular adhesion molecule (ICAM) and platelet endothelial cell adhesion molecule (PECAM), as well as increased formation of endothelial tubes. The findings of this study emphasize a critical demand for further characterization and analyses of distinct M2 subtypes and careful selection of specific macrophage populations for regeneration of specific tissue types. The current, broad classification of “M2” may be sufficient in many general tissue engineering applications, but, as conditions are constantly in flux within the microenvironment in vivo, a higher degree of specificity and control over the initial M2 subtype could result in more consistent long‐term outcomes where macrophages are utilized as part of an overall regenerative strategy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Tissue Engineering and Regenerative Medicine · Mesenchymal stem cell research · Wound Healing and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology Weill Cornell Medicine New York New York USA

Department of Mechanical and Aerospace Engineering Case Western Reserve University Cleveland Ohio USA

Department of Urology Case Western Reserve University Cleveland Ohio USA

Case Western Reserve University Department of Genetics and Genome Sciences Cleveland Ohio USA

Department of Anatomy and Neurobiology Northeast Ohio Medical University (NEOMED) Rootstown Ohio USA

Department of Pathology Case Western Reserve University Cleveland Ohio USA

Department of Biomedical Engineering Case Western Reserve University Cleveland Ohio USA

Department of Orthopedics Case Western Reserve University Cleveland Ohio USA

Funding

Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University · National Institutes of Health

References (66)

Show source-provided references
1. 10.1177/002203450935912510.1177/0022034509359125 ↗
2. 10.1152/physrev.00067.201710.1152/physrev.00067.2017 ↗
3. 10.1016/j.semcdb.2016.08.00610.1016/j.semcdb.2016.08.006 ↗
4. 10.1016/j.immuni.2014.06.01310.1016/j.immuni.2014.06.013 ↗
5. 10.1189/jlb.050427210.1189/jlb.0504272 ↗
6. 10.1038/nri307310.1038/nri3073 ↗
7. 10.1089/wound.2011.030710.1089/wound.2011.0307 ↗
8. 10.3389/fimmu.2019.0108410.3389/fimmu.2019.01084 ↗
9. 10.1146/annurev.pharmtox.010909.10581210.1146/annurev.pharmtox.010909.105812 ↗
10. 10.3389/fimmu.2014.0053310.3389/fimmu.2014.00533 ↗
11. 10.1016/j.immuni.2010.05.00710.1016/j.immuni.2010.05.007 ↗
12. 10.1016/j.immuni.2016.02.01510.1016/j.immuni.2016.02.015 ↗
13. 10.1016/j.addr.2017.05.01010.1016/j.addr.2017.05.010 ↗
14. 10.1155/2014/56062910.1155/2014/560629 ↗
15. 10.1186/s11658-022-00384-y10.1186/s11658-022-00384-y ↗
16. 10.1530/REP-16-015910.1530/REP-16-0159 ↗
17. 10.2337/db11-163510.2337/db11-1635 ↗
18. 10.1042/CS2022053110.1042/CS20220531 ↗
19. A spatial map of human macrophage niches reveals context‐dependent macrophage functions in colon and breast cancer
20. 10.1016/j.actbio.2021.06.04310.1016/j.actbio.2021.06.043 ↗
21. 10.1089/ten.tea.2021.020310.1089/ten.tea.2021.0203 ↗
22. 10.26508/lsa.20200095710.26508/lsa.202000957 ↗
23. 10.1016/j.imbio.2020.15193510.1016/j.imbio.2020.151935 ↗
24. 10.1371/journal.pone.001526310.1371/journal.pone.0015263 ↗
25. 10.3389/fimmu.2019.0079210.3389/fimmu.2019.00792 ↗
26. 10.1007/978-1-4939-7837-3_1210.1007/978-1-4939-7837-3_12 ↗
27. 10.1016/j.jdermsci.2021.08.00810.1016/j.jdermsci.2021.08.008 ↗
28. A Matrigel‐based tube formation assay to assess the vasculogenic activity of tumor cells
29. 10.3389/fimmu.2021.70818610.3389/fimmu.2021.708186 ↗
30. 10.1172/JCI12461510.1172/JCI124615 ↗
31. 10.1016/j.niox.2020.04.00510.1016/j.niox.2020.04.005 ↗
32. 10.1161/CIRCRESAHA.116.30919410.1161/CIRCRESAHA.116.309194 ↗
33. 10.1016/j.cell.2010.03.01410.1016/j.cell.2010.03.014 ↗
34. 10.1177/030098581246988310.1177/0300985812469883 ↗
35. 10.4103/2347-9264.16543810.4103/2347-9264.165438 ↗
36. 10.1089/wound.2013.051710.1089/wound.2013.0517 ↗
37. 10.18632/oncotarget.2033110.18632/oncotarget.20331 ↗
38. 10.1101/cshperspect.a00509010.1101/cshperspect.a005090 ↗
39. 10.1002/JLB.2MR0220-549R10.1002/JLB.2MR0220-549R ↗
40. 10.1007/BF0020206910.1007/BF00202069 ↗
41. 10.1016/0167-5699(94)90195-310.1016/0167-5699(94)90195-3 ↗
42. 10.12688/f1000research.7010.110.12688/f1000research.7010.1 ↗
43. 10.3389/fimmu.2014.0049110.3389/fimmu.2014.00491 ↗
44. 10.1038/s41536-021-00193-510.1038/s41536-021-00193-5 ↗
45. 10.4049/jimmunol.110318010.4049/jimmunol.1103180 ↗
46. 10.1161/ATVBAHA.113.30145310.1161/ATVBAHA.113.301453 ↗
47. 10.1016/j.imbio.2005.05.01010.1016/j.imbio.2005.05.010 ↗
48. 10.3390/ijms1807154510.3390/ijms18071545 ↗
49. 10.1089/wound.2013.048510.1089/wound.2013.0485 ↗
50. 10.1186/1478-811X-11-2910.1186/1478-811X-11-29 ↗
51. 10.1016/j.immuni.2015.09.00510.1016/j.immuni.2015.09.005 ↗
52. 10.3389/fimmu.2015.0060210.3389/fimmu.2015.00602 ↗
53. 10.1155/2015/81646010.1155/2015/816460 ↗
54. 10.3389/fonc.2019.0137010.3389/fonc.2019.01370 ↗
55. 10.21037/atm.2019.02.4710.21037/atm.2019.02.47 ↗
56. 10.1016/j.jid.2015.12.01010.1016/j.jid.2015.12.010 ↗
57. 10.1177/147916411558235110.1177/1479164115582351 ↗
58. 10.1182/blood-2013-05-50149410.1182/blood-2013-05-501494 ↗
59. 10.1111/imr.1222310.1111/imr.12223 ↗
60. 10.3389/fimmu.2020.59459410.3389/fimmu.2020.594594 ↗
61. 10.3390/ma809526910.3390/ma8095269 ↗
62. 10.1016/j.actbio.2021.03.03810.1016/j.actbio.2021.03.038 ↗
63. 10.3389/fbioe.2020.60929710.3389/fbioe.2020.609297 ↗
64. 10.1177/153537021665029310.1177/1535370216650293 ↗
65. 10.1016/j.mtbio.2023.10078310.1016/j.mtbio.2023.100783 ↗
66. 10.1038/s41392-023-01452-110.1038/s41392-023-01452-1 ↗